The 63 references in paper A. Vatazin V., A. Zulkarnaev B., А. Ватазин В., А. Зулькарнаев Б. (2017) “ЭНДОТОКСИН И ХРОНИЧЕСКОЕ ВОСПАЛЕНИЕ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК // ENDOTOXIN AND CHRONIC INFLAMMATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE” / spz:neicon:nefr:y:2016:i:6:p:26-32

1
Бикбов БТ, Томилина НА. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 1998-2013 гг. Отчет по данным российского регистра заместительной почечной терапии. Часть первая. Нефрология и диализ 2015; 17(3, приложение): 5-111 [Bikbov BT, Tomilina NA. Zamestitel’naja terapija terminal’noj hronicheskoj pochechnoj nedostatochnosti v rossijskoj federacii v 1998-2013 gg. Otchet po dannym rossijskogo registra zamestitel’noj pochechnoj terapii. Chast’ pervaja. Nefrologija i dializ 2015; 17(3, prilozhenie): 5-111]
(check this in PDF content)
2
Terawaki H, Yokoyama, Yamada Y et al. Low-grade endotoxemia contributes to chronic inflammation in hemodialysis patients: examination with a novel lipopolysaccharide detection method. Ther Apher Dial 2010; 14(5):477-482. doi: 10.1111/j.17449987.2010.00815.x
(check this in PDF content)
3
McIntyre CW, Harrison LE, Eldehni MT et al. Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(1):133-141. doi: 10.2215/CJN.04610510
(check this in PDF content)
4
Cardoso PG, Macedo GC, Azevedo V et al. Brucella spp noncanonical LPS: structure, biosynthesis, and interaction with host immune system. Microb Cell Fact 2006; 5:13
(check this in PDF content)
5
Villar J, Maca-Meyer N, Pérez-Méndez L et al. Bench-tobedside review: understanding genetic predisposition to sepsis. Crit Care 2004; 8(3): 180-189
(check this in PDF content)
6
Gyorfy Z, Duda E, Vizler C. Interactions between LPS moieties and macrophage pattern recognition receptors. Vet Immunol Immunopathol 2013; 152(1-2):28-36. doi: 10.1016/j. vetimm.2012.09.020
(check this in PDF content)
7
Аниховская ИА, Опарина ОН, Яковлева ММ, Яковлев МЮ. Кишечный эндотоксин как универсальный фактор адаптации и патогенеза общего адаптационного синдрома. Физиология человека 2006; 32(2): 87-91
(check this in PDF content)
8
Ward PA. Role of C5 activation products in sepsis. ScientificWorldJournal 2010; 10:2395-2402. doi: 10.1100/tsw.2010.216
(check this in PDF content)
9
Kozarcanin H, Lood C, Munthe-Fog L et al. The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation. J Thromb Haemost 2016; 14(3):531-545. doi: 10.1111/jth.13208
(check this in PDF content)
10
Esmon CT, Xu J, Lupu F. Innate immunity and coagulation. J Thromb Haemost 2011; 9 Suppl 1:182-188. doi: 10.1111/j.15387836.2011.04323.x
(check this in PDF content)
11
Lassenius MI, Pietiläinen KH, Kaartinen K et al. Bacterial endotoxin activity in human serum is associated with dyslipidemia, insulin resistance, obesity, and chronic inflammation. Diabetes Care 2011; 34(8):1809-1815. doi: 10.2337/dc10-2197
(check this in PDF content)
12
Boutagy NE, McMillan RP, Frisard MI et al. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie 2016; 124:11-20. doi: 10.1016/j.biochi.2015.06.020
(check this in PDF content)
13
Белоглазов ВА, Климчук АВ, Гордиенко АИ и др. Динамика показателей гуморального антиэндотоксинового иммунитета и уровень С-реактивного белка у больных хронической болезнью почек, находящихся на программном гемодиализе, при четырехлетнем наблюдении. Нефрология и диализ 2013; 15(2): 140-143 [Beloglazov VA, Klimchuk AV, Gordienko AI i dr. Dinamika pokazatelej gumoral'nogo antijendotoksinovogo immuniteta i uroven' S-reaktivnogo belka u bol'nyh hronicheskoj bolezn'ju pochek, nahodjashhihsja na programmnom gemodialize, pri chetyrehletnem nabljudenii. Nefrologija i dializ 2013; 15(2): 140-143]
(check this in PDF content)
14
Feroze U, Kalantar-Zadeh K, Sterling KA et al. Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012; 22(3):317-326. doi: 10.1053/j.jrn.2011.05.004
(check this in PDF content)
15
Lau WL, Kalantar-Zadeh K, Vaziri ND. The Gut as a Source of Inflammation in Chronic Kidney Disease. Nephron 2015; 130(2):92-98. doi: 10.1159/000381990
(check this in PDF content)
16
Sabatino A, Regolisti G, Brusasco I et al. Alterations of intestinal barrier and microbiota in chronic kidney disease. Nephrol Dial Transplant 2015; 30(6):924-933. doi: 10.1093/ndt/gfu287
(check this in PDF content)
17
Shi K, Wang F, Jiang H et al. Gut bacterial translocation may aggravate microinflammation in hemodialysis patients. Dig Dis Sci 2014; 59(9):2109-2117. doi: 10.1007/s10620-014-3202-7
(check this in PDF content)
18
Hazzah WA, Hashish MH, El-Koraie AF et al. Circulating bacterial DNA fragments in chronic hemodialysis patients. Saudi J Kidney Dis Transpl 2015; 26(6):1300-1304. doi: 10.4103/13192442.168689
(check this in PDF content)
19
Marinho AC, Polay AR, Gomes BP. Accuracy of Turbidimetric Limulus Amebocyte Lysate Assay for the Recovery of Endotoxin Interacted with Commonly Used Antimicrobial Agents of Endodontic Therapy. J Endod 2015; 41(10):1653-1659. doi: 10.1016/j.joen.2015.05.020
(check this in PDF content)
20
Wong J, Vilar E, Farrington K. Endotoxemia in end-stage kidney disease. Semin Dial; 28(1):59-67. doi: 10.1111/sdi.12280
(check this in PDF content)
21
Shimizu T, Obata T, Sonoda H et al. Diagnostic potential of endotoxin scattering photometry for sepsis and septic shock. Shock 2013; 40(6):504-511. doi: 10.1097/SHK.0000000000000056
(check this in PDF content)
22
Ding JL, Ho B. Endotoxin detection-from limulus amebocyte lysate to recombinant factor C. Subcell Biochem 2010; 53:187-208. doi: 10.1007/978-90-481-9078-2_9
(check this in PDF content)
23
Yaguchi A, Yuzawa J, Klein DJ et al. Combining intermediate levels of the Endotoxin Activity Assay (EAA) with other biomarkers in the assessment of patients with sepsis: results of an observational study. Crit Care 2012; 16(3):R88. doi: 10.1186/ cc11350
(check this in PDF content)
24
Poesen R, Ramezani A, Claes K et al. Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. Clin J Am Soc Nephrol 2015; 10(9):1525-1533. doi: 10.2215/ CJN.03100315.
(check this in PDF content)
25
Raj DS, Shah VO, Rambod M et al. Association of soluble endotoxin receptor CD14 and mortality among patients undergoing hemodialysis. Am J Kidney Dis 2009; 54(6):1062-1071. doi: 10.1053/j.ajkd.2009.06.028
(check this in PDF content)
26
Cobo G, Qureshi AR, Lindholm B, Stenvinkel P. C-reactive Protein: Repeated Measurements will Improve Dialysis Patient Care. Semin Dial 2016; 29(1):7-14. doi: 10.1111/sdi.12440
(check this in PDF content)
27
Cross AS. Development of an anti-endotoxin vaccine for sepsis. Subcell Biochem 2010; 53: 285-302
(check this in PDF content)
28
Müller-Loennies S, Brade L, Brade H. Neutralizing and cross-reactive antibodies against enterobacterial lipopolysaccharide. Int J Med Microbiol 2007; 297(5): 321-340
(check this in PDF content)
29
Santos MF, New RR, Andrade GR et al. Lipopolysaccharide as an antigen target for the formulation of a universal vaccine against Escherichia coli O111 strains. Clin Vaccine Immunol 2010; 17(11): 1772-1780
(check this in PDF content)
30
Harkin DW, Arnold R, Hoper M. Anti-endotoxin hyperimmune globulin attenuates portal cytokinaemia, phagocytic cell priming, and acute lung injury after lower limb ischaemiareperfusion injury. Eur J Vasc Endovasc Surg 2007; 33(3): 330-339
(check this in PDF content)
31
Pini A, Falciani C, Mantengoli E et al. A novel tetrabranched antimicrobial peptide that neutralizes bacterial lipopolysaccharide and prevents septic shock in vivo. FASEB J 2010; 24(4): 1015-1022
(check this in PDF content)
32
Li J, Shang G, You M et al. Endotoxin removing method based on lipopolysaccharide binding protein and polyhydroxyalkanoate binding protein PhaP. Biomacromolecules 2011; 12(3): 602-608
(check this in PDF content)
33
Liu D, Lu F, Qin G et al. C1 inhibitor-mediated protection from sepsis. J Immunol 2007; 179(6): 3966-3972
(check this in PDF content)
34
Kaconis Y, Kowalski I, Howe J et al. Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 2011; 100(11): 2652-6261
(check this in PDF content)
35
Peri F, Piazza M. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Biotechnol Adv 2012; 30(1): 251-260
(check this in PDF content)
36
Fujita T. Molecular mechanism of endotoxin tolerance. Hepatology 2009; 50(4): 1322
(check this in PDF content)
37
Brandenburg K, Heinbockel L, Correa W et al. Peptides with dual mode of action: Killing bacteria and preventing endotoxininduced sepsis. Biochim Biophys Acta 2016; 1858(5):971-979. doi: 10.1016/j.bbamem.2016.01.011
(check this in PDF content)
38
Sun Y, Shang D. Inhibitory Effects of Antimicrobial Peptides on Lipopolysaccharide-Induced Inflammation. Mediators Inflamm 2015; 2015:167572. doi: 10.1155/2015/167572
(check this in PDF content)
39
Moraes C, Fouque D, Amaral AC et al. Trimethylamine N-Oxide From Gut Microbiota in Chronic Kidney Disease Patients: Focus on Diet. J Ren Nutr 2015; 25(6):459-465. doi: 10.1053/j. jrn.2015.06.004
(check this in PDF content)
40
Machowska A, Carrero JJ, Lindholm B et al. Therapeutics targeting persistent inflammation in chronic kidney disease. Transl Res 2016; 167(1):204-213. doi: 10.1016/j.trsl.2015.06.012
(check this in PDF content)
41
Tzanno-Martins C, Biavo BM, Ferreira-Filho O et al. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Int J Immunopathol Pharmacol 2014; 27(1):25-35
(check this in PDF content)
42
Rossi M, Johnson DW, Campbell KL. The Kidney-Gut Axis: Implications for Nutrition Care. J Ren Nutr 2015; 25(5):399-403. doi: 10.1053/j.jrn.2015.01.017
(check this in PDF content)
43
Sun PP, Perianayagam MC, Jaber BL. Endotoxinbinding affinity of sevelamer: a potential novel anti-inflammatory mechanism. Kidney Int Suppl 2009; (114):S20-5. doi: 10.1038/ ki.2009.403
(check this in PDF content)
44
Rodríguez-Osorio L, Zambrano DP, Gracia-Iguacel C et al. Use of sevelamer in chronic kidney disease: beyond phosphorus control. Nefrologia 2015; 35(2):207-217. doi: 10.1016/j. nefro.2015.05.022
(check this in PDF content)
45
Mafra D, Fouque D. Gut microbiota and inflammation in chronic kidney disease patients. Clin Kidney J 2015; 8(3):332-334. doi: 10.1093/ckj/sfv026
(check this in PDF content)
46
Wing MR, Patel SS, Ramezani A et al. Gut microbiome in chronic kidney disease. Exp Physiol 2016; 101(4):471-477. doi: 10.1113/EP085283
(check this in PDF content)
47
Coulliette AD, Arduino MJ. Hemodialysis and water quality. Semin Dial 2013; 26(4):427-438. doi: 10.1111/sdi.12113
(check this in PDF content)
48
Schiffl H. High-flux dialyzers, backfiltration, and dialysis fluid quality. Semin Dial 2011; 24(1):1-4. doi: 10.1111/j.1525139X.2010.00786.x
(check this in PDF content)
49
Glorieux G, Hulko M, Speidel R et al. Looking beyond endotoxin: a comparative study of pyrogen retention by ultrafilters used for the preparation of sterile dialyis fluid. Sci Rep 2014; 4:6390. doi: 10.1038/srep06390
(check this in PDF content)
50
Kashiwagi T, Sato K, Kawakami S et al. The performance evaluation of endotoxin retentive filters in haemodialysis. J Nippon Med Sch 2011; 78(4):214-223
(check this in PDF content)
51
Glorieux G, Neirynck N, Veys N, Vanholder R. Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant 2012; 27(11):4010-4021. doi: 10.1093/ndt/gfs306
(check this in PDF content)
52
Bowry SK, Gatti E, Vienken J. Contribution of polysulfone membranes to the success of convective dialysis therapies. Contrib Nephrol 2011; 173:110-118. doi: 10.1159/000328960
(check this in PDF content)
53
Thomas M, Moriyama K, Ledebo I. AN69: Evolution of the world’s first high permeability membrane. Contrib Nephrol 2011; 173:119-129. doi: 10.1159/000328961
(check this in PDF content)
54
Perego AF. Adsorption techniques: dialysis sorbents and membranes. Blood Purif 2013; 35 Suppl 2:48-51. doi: 10.1159/000350848
(check this in PDF content)
55
Aucella F, Gesuete A, Vigilante M et al. Adsorption dialysis: from physical principles to clinical applications. Blood Purif 2013; 35 Suppl 2:42-47. doi: 10.1159/000350847
(check this in PDF content)
56
Tijink MS, Wester M, Sun J et al. A novel approach for blood purification: mixed-matrix membranes combining diffusion and adsorption in one step. Acta Biomater 2012; 8(6):2279-2287. doi: 10.1016/j.actbio.2012.03.008
(check this in PDF content)
57
Tijink MS, Kooman J, Wester M et al. Mixed matrix membranes: a new asset for blood purification therapies. Blood Purif 2014; 37(1):1-3. doi: 10.1159/000356226
(check this in PDF content)
58
Li L, Ling Y, Huang M et al. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages. Cytokine 2015; 72(1):3642. doi: 10.1016/j.cyto.2014.12.010
(check this in PDF content)
59
Li X, Liu Y, Wang L et al. Unfractionated heparin attenuates LPS-induced IL-8 secretion via PI3K/Akt/NF-κB signaling pathway in human endothelial cells. Immunobiology 2015; 220(3):399-405. doi: 10.1016/j.imbio.2014.10.008
(check this in PDF content)
60
Li X, Li X, Zheng Z et al. Unfractionated heparin suppresses lipopolysaccharide-induced monocyte chemoattractant protein-1 expression in human microvascular endothelial cells by blocking Krüppel-like factor 5 and nuclear factor-κB pathway. Immunobiology 2014; 219(10):778-785. doi: 10.1016/j.imbio.2014.06.005
(check this in PDF content)
61
Li X, Zheng Z, Li X, Ma X. Unfractionated heparin inhibits lipopolysaccharide-induced inflammatory response through blocking p38 MAPK and NF-κB activation on endothelial cell. Cytokine 2012; 60(1):114-121. doi: 10.1016/j.cyto.2012.06.008
(check this in PDF content)
62
Li X, Zheng Z, Mao Y, Ma X. Unfractionated heparin promotes LPS-induced endothelial barrier dysfunction: a preliminary study on the roles of angiopoietin/Tie2 axis. Thromb Res 2012; 129(5):e223-228. doi: 10.1016/j.thromres.2012.03.003
(check this in PDF content)
63
Luan ZG, Naranpurev M, Ma XC. Treatment of low molecular weight heparin inhibits systemic inflammation and prevents endotoxin-induced acute lung injury in rats. Inflammation 2014; 37(3):924-932. doi: 10.1007/s10753-014-9812-6 Сведения об авторах:
(check this in PDF content)